Half-year report January-June 2007

Half-year report January-June 2007

• Net sales increased by 10 percent to SEK 96.8 (88.4) million. Adjusted for
exchange rate effects, the increase was 13 percent. During the second quarter
sales amounted to SEK 47.5 (42.5) million, corresponding to an increase of 12
percent.

• Gross income increased by 13 percent to SEK 67.0 (59.2) million, and the gross
margin improved to 69 percent (67). Gross income for the second quarter
increased by 14 percent to SEK 33.3 (29.1) million and the gross margin was 70
(69) percent.

• Operating income increased by 44 percent and amounted to SEK 13.8 (9.6)
million, which gives an operating margin of 14 percent (11). For the second
quarter operating income amounted to SEK 5.9 (4.2) million.

• Operating income before research and development costs increased by 25 percent
to SEK 27.0 (21.6) million. This corresponds to a margin of 28 percent (24). For
the second quarter the increase was 22 percent to SEK 12.4 (10.2) million, a
margin of 26 percent (24).

• Continued strong focus on research and development activities, 13.6 percent
(13.6) of sales, 13.8 percent (14.3) for the second quarter.

• Consolidated net income increased to SEK 20.5 (7.1) million. Capitalization of
the deferred tax asset in loss carry-forward for tax purposes has been carried
out to the tune of SEK 8.2 (-) million. The figures for the second quarter were
SEK 9.5 (2.8) million and SEK 4.1 (-) million, respectively.

• The cash flow from operating activities increased to SEK 12.3 (8.5) million,
of which SEK 7.3 (8.0) was for the second quarter.

• Earnings per share increased to SEK 1.04 (0.36) of which SEK 0.48 (0.14) was
for the second quarter.

• The equity/assets ratio amounted to 83 percent (78).

• Launch of a new product series within Fertility, the G5 Series™, was begun
after the end of the period.

• New agreement with Cellartis within the development of new stem cell media.


July 13, 2007
Kungsbacka, Sweden 

The Board and the CEO




Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.


________________________________________________________________________________
_________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. The Fertility product area works with
nutrient solutions (media) and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to maintain tissue in optimal
condition outside the body for the required time while waiting for
transplantation. The Stem Cell Cultivation product area works with media and
instruments to enable the use and handling of stem cells for therapeutic
purposes. 
     Vitrolife today has approximately 130 employees and the company's products
are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and
there are subsidiaries outside Gothenburg, Sweden and in Denver, USA. The
Vitrolife share is listed on the OMX Nordic Exchange's Nordic Small Cap list.
________________________________________________________________________________
_________
Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate
identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.